Kazia Therapeutics Limited
KZIA
$13.25
$3.1931.71%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 2.27% | -- | |||
| Total Other Revenue | 2.11% | 7,482.19% | |||
| Total Revenue | 2.12% | 7,663.01% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 2.12% | 7,663.01% | |||
| SG&A Expenses | 2.12% | -31.95% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.12% | -31.77% | |||
| Operating Income | -2.12% | 50.18% | |||
| Income Before Tax | -2.12% | -7.81% | |||
| Income Tax Expenses | -2.12% | -1,042.76% | |||
| Earnings from Continuing Operations | -2.12% | 5.63% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.12% | 5.63% | |||
| EBIT | -2.12% | 50.18% | |||
| EBITDA | -5.89% | 51.77% | |||
| EPS Basic | -2.12% | 40.18% | |||
| Normalized Basic EPS | -2.12% | 71.57% | |||
| EPS Diluted | -2.12% | 40.18% | |||
| Normalized Diluted EPS | -2.12% | 71.57% | |||
| Average Basic Shares Outstanding | 0.00% | 57.76% | |||
| Average Diluted Shares Outstanding | 0.00% | 52.94% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||